Pharmacopsychiatry 2002; 35(6): 220-225
DOI: 10.1055/s-2002-36390
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Body Weight, the Tumor Necrosis Factor System, and Leptin Production during Treatment with Mirtazapine or Venlafaxine

T. Kraus1 , M. Haack1 , A. Schuld1 , D. Hinze-Selch2 , D. Koethe1 , T. Pollmächer1
  • 1Max Planck Institute of Psychiatry, Munich, Germany
  • 2Department of Psychiatry and Psychotherapy, Christian Albrechts University, Kiel, Germany
Further Information

Publication History

Received: 6. 12. 2001 Revised: 20. 3. 2002

Accepted: 20. 3. 2002

Publication Date:
20 December 2002 (online)

Preview

Weight gain is a frequent and important side effect of psychopharmacotherapy. Recent studies suggest that the fat-cell-derived hormone leptin and the tumor necrosis factor-α (TNF-α) cytokine system are pathophysiologically involved. No information is available concerning the influence of the antidepressants mirtazapine and venlafaxine on these immunoendocrine variables. An open-labeled study was performed in 20 patients suffering from major depression treated with either mirtazapine (N = 11) or venlafaxine (N = 9). During 4 weeks, the patients’ weight, body mass index (BMI), and plasma levels of leptin, TNF-α, sTNF-R p55, and sTNF-R p75 were assessed. Mirtazapine induced a significant increase in weight (mean weight gain: 2.4 kg) that was evident after the first week of treatment. In parallel, the plasma levels of TNF-α and both soluble TNF receptors increased. In addition, a slight rise in leptin levels, which occurred slowly and was significant only at the end of the 4th week of treatment, was observed. Weight decreased slightly but significantly in patients treated with venlafaxine (mean weight loss: 0.4 kg), whereas plasma levels of leptin, TNF-α, or soluble TNF receptors did not change significantly. The present results further support the notion that the activation of the TNF-α cytokine system is an early, sensitive, and specific marker of weight gain induced by psychotropic agents. In contrast, the effects of such drugs on leptin production seem to be less sensitive with respect to weight gain and more variable.

References

Thomas Pollmächer, M.D. 

Max Planck Institute of Psychiatry

Kraepelinstrasse 10

80804 Munich

Germany

Phone: (+49) 89 30622 572

Fax: (+49) 89 30622 562

Email: topo@mpipsykl.mpg.de